In the DECREASE-III trial, 497 statin-naive patients undergoing elective vascular surgery (carotid, aortic, or lower extremity) were randomized to fluvastatin 80mg or placebo (for 1 month before and 1 month after surgery). The statin group experienced less myocardial ischemia (11% vs 19%) and non-fata MI/CV death (5% vs 10%). Critics state that most of these patients should have been on statins anyway, and that starting peri-operative statins on all vascular surgery patients may not be warranted (abstract).
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment